- |||||||||| Clinical, Retrospective data, Review, Journal: Prevalence and risk factors of sarcopenia in patients with stroke: a systematic review and meta-analysis. (Pubmed Central) - Dec 27, 2024
Age, low albumin, low hemoglobin, stroke duration, length of hospital stay, and pneumonia history were the risk factors for sarcopenia in patients with stroke. This review will provide evidence for the screening and early identification of high-risk groups and the prevention of sarcopenia to improve the quality of life of stroke patients.
- |||||||||| Review, Journal: Spotlight on the Mechanism of Action of Semaglutide. (Pubmed Central) - Dec 27, 2024
Moreover, possible applications in protection from infections and anti-aging properties are discussed. Semaglutide enhancement of the core molecular mechanisms involved in the progress of obesity and diabetes, although mostly preclinical, may provide a framework for future research applications in human diseases overall.
- |||||||||| Journal: Wearable Fabric System for Sarcopenia Detection. (Pubmed Central) - Dec 27, 2024
Moreover, this fabric system can be seamlessly integrated into sole to track critical indicators of sarcopenia patients, such as walking speed and gait. Clinical evaluations have shown that this fabric system can effectively detect variations in indicators relevant to sarcopenia patients, proving that it offers a straightforward and promising approach for the diagnosis and assessment of sarcopenia.
- |||||||||| Trial completion date, Trial primary completion date: M&M: Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults With Colorectal Cancer (clinicaltrials.gov) - Dec 27, 2024
P=N/A, N=300, Recruiting, A BIA allows for the detection of changes in body composition in survivors of childhood brain tumors, revealing either the presence of central obesity correlated with the risk of MetS or signs of sarcopenia that deserve early treatment. Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Dec 2025
- |||||||||| Journal: Sarcopenia Seems to Be Common in Older Patients With Restless Legs Syndrome. (Pubmed Central) - Dec 26, 2024
This study demonstrated that sarcopenia is prevalent among older patients with RLS, which seems to be associated with low muscle strength and slow gait speed. Given the negative health outcomes related to sarcopenia, interventions aimed at preventing its development could be significantly beneficial for patients with RLS in older adults as well.
- |||||||||| Trial completion date, Trial primary completion date: The Effects of Eccentric Cycling Exercise Program in Chronic Kidney Disease Patients (clinicaltrials.gov) - Dec 26, 2024
P=N/A, N=90, Recruiting, The study's small sample size calls for further research with more diverse and gender-balanced groups to verify these results. Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Oct 2024 --> Jun 2026
- |||||||||| Retrospective data, Review, Journal: Sarcopenia and risk of postoperative pneumonia: a systematic review and meta-analysis. (Pubmed Central) - Dec 25, 2024
Our research findings indicate that preoperative sarcopenia significantly increases the risk of postoperative pneumonia. Future high-quality prospective studies and intervention studies are needed to validate the relationship between sarcopenia and postoperative pneumonia and improve patient outcomes.
- |||||||||| Review, Journal: Muscle mass, muscle strength and the renin-angiotensin system. (Pubmed Central) - Dec 24, 2024
This has led to a new understanding of the physiological function of the RAS in skeletal muscle. This review summarizes the diverse physiological functions of the RAS in skeletal muscle and considers the potential of future therapeutic strategies targeting the RAS to overcome problems such as sarcopenia and muscle weakness associated with chronic disease.
- |||||||||| Clinical, Clinical protocol, Journal: The effect of Sarcomeal (Pubmed Central) - Dec 24, 2024
Outcomes will be assessed at one of or all the time points of baseline, 12 and 24 It is hypothesized that the Sarcomeal
- |||||||||| Review, Journal: Chaperone Proteins: The Rising Players in Muscle Atrophy. (Pubmed Central) - Dec 21, 2024
This highlights the therapeutic potential of targeting chaperones and confirms their crucial anti-atrophic functions. In this review, we summarize the most relevant data showing the modulation and the causative role of chaperone proteins in different types of skeletal muscle atrophies.
- |||||||||| Preclinical, Journal: Differential effects of EPA and DHA on aging-related sarcopenia in mice and possible mechanisms involved. (Pubmed Central) - Dec 20, 2024
Moreover, EPA also revealed a better effect on inhibiting mitochondria- and endoplasmic reticulum stress-mediated apoptosis in aged skeletal muscle. Furthermore, EPA manifested a more pronounced effect on improving mitochondrial damage of aged skeletal muscle than DHA, and the reason might be due to its superior capability of regulating mitochondrial quality control, as clearly shown by enhancing mitochondrial biogenesis through the AMPK/PGC-1?-dependent pathway, restraining the loss of mitochondrial fusion and fission proteins including Opa1, Mfn2, and Fis1, and promoting mitophagy via the PINK1/Parkin-dependent pathway.
- |||||||||| Retrospective data, Review, Journal: Comment on "Circulating irisin levels in patients with sarcopenia: a systematic review and meta-analysis". (Pubmed Central) - Dec 20, 2024
Furthermore, EPA manifested a more pronounced effect on improving mitochondrial damage of aged skeletal muscle than DHA, and the reason might be due to its superior capability of regulating mitochondrial quality control, as clearly shown by enhancing mitochondrial biogenesis through the AMPK/PGC-1?-dependent pathway, restraining the loss of mitochondrial fusion and fission proteins including Opa1, Mfn2, and Fis1, and promoting mitophagy via the PINK1/Parkin-dependent pathway. No abstract available
|